United States Patent 5,164,190: Scope, Claims, and Patent Landscape Analysis
Introduction
United States Patent 5,164,190 (the '190 patent), granted on November 17, 1992, represents a significant intellectual property asset in the pharmaceutical industry. This analysis dissects its scope and claims, contextualizes its coverage within the broader patent landscape, and assesses implications for contemporaneous and future drug development activities.
Scope and Core Claims of Patent 5,164,190
Overview
The '190 patent pertains to a class of pharmaceutical compounds with specific chemical structures, primarily focused on therapeutic effects in the treatment of neurological disorders, notably depression and anxiety. The patent claims both the compounds themselves and methods for their preparation and therapeutic use.
Principal Claims
- Claim 1: Encompasses a class of compounds characterized by a core chemical structure—benzazepine derivatives—substituted in a manner designed to modulate serotoninergic and noradrenergic pathways.
- Claims 2-10: Specify particular chemical variations within the broad class, covering specific substitutions on the core structure. These define the scope of the compounds' chemical diversity.
- Claims 11-13: Cover methods of synthesizing these compounds, including specific reaction pathways and intermediates.
- Claims 14-20: Encompass pharmaceutical compositions comprising the claimed compounds and their use in treating depression, anxiety, and other CNS disorders.
- Claims 21-23: Provide methods for administering these compounds, including dosage forms, routes of administration, and treatment regimens.
Scope Analysis
The patent's claims obliquely target both chemical entities (compounds) and therapeutic methods, following conventional paradigms of pharmaceutical patents. Its claims are relatively broad in covering benzazepine derivatives with specific substituents, allowing some flexibility over exact molecular formulas.
However, the specificity within the claims—particularly in the embedded chemical substitutions—limits the scope to certain compound subclasses, reducing vulnerability to design-around strategies that employ alternative chemical scaffolds.
Patent Landscape Context
Historical Context and Priority
The '190 patent was filed in 1989, with priority dates aligning with the late 1980s. During this period, the pharmaceutical industry notably invested in serotonergic and noradrenergic agents to treat CNS disorders, with selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs) emerging as leading drug classes.
Key Patents and Related Milestones
- Prior Art Citations: The patent references prior art in benzazepine derivatives and serotonergic agents, indicating an intent to improve upon existing therapies with compounds exhibiting enhanced efficacy or safety.
- Competitive Patents: Similar patents surfaced in the late '80s and early '90s, covering different chemical scaffolds such as tricyclics and heterocycles targeted at CNS pharmacotherapy (e.g., U.S. Patent 4,482,550).
Post-Grant Patent Position
Subsequent patents have paved the way for second-generation compounds emphasizing selectivity and reduced side-effects. Patent landscapes for drugs in this space tend to be crowded, with overlapping claims around chemical classes, methods of use, and formulations—a common scenario in CNS pharmacology.
Patent Term & Expiry
Given the filing date (1989), the '190 patent would have expired around 2006, considering 17-year patent term from issuance plus possible term adjustments. Expiry opens the space for generic development.
Implications for Drug Development and Market Position
Patent Strength
- The claims are sufficiently broad to cover multiple benzazepine derivatives, susceptible to generic competition post-expiration.
- Specificity in chemical variations provides strong protection for particular compounds but leaves room for innovation around alternative scaffolds or asymmetric substitutions.
Freedom-to-Operate
- Investors or developers aiming to commercialize drugs similar to the '190 patent’s scope can explore alternative chemical classes or additional novel uses, given the patent's age and scope.
Strategic Considerations
- Due to possible overlaps with other patents in CNS agents, due diligence should verify freedom-to-operate, especially for molecules modifying serotonergic pathways.
- The patent’s expiration encourages patent filers to seek secondary patents around formulations, methods of administration, or specific therapeutic indications.
Broader Patent Landscape Assessments
Chemical Class Focus
Benzazepine derivatives, like those claimed by the '190 patent, are part of a larger patent landscape involving multiple heterocyclic structures targeting serotonin receptors, indicative of an active innovation zone during the late 20th century.
Method of Use and Formulation Patents
Innovation has shifted towards optimizing drug delivery, patient compliance, and combination therapies. While the '190 patent mainly covers chemical compounds, subsequent patents might focus on novel formulations or delivery methods that extend market exclusivity.
Competitive Patents and Litigation
Multiple patent litigations during this era, especially relating to serotonin receptor antagonists and reuptake inhibitors, suggest intense patenting activity, which can impact generic entry strategies.
Conclusion
The '190 patent offers a moderate scope aligned with benzazepine derivatives targeting CNS disorders, particularly depression. Its claims encompass a targeted chemical class and therapeutic methods but are limited in scope by specific substitutions. As it has expired, the patent landscape is now open for generic and biosimilar development. Nonetheless, its legacy continues in subsequent patents that refine, optimize, or expand upon these chemical frameworks.
Key Takeaways
- The '190 patent's broad claims on benzazepine derivatives provided substantial protection during its active period, but structural specificity limits its scope.
- The patent landscape in CNS therapeutics from the late 20th century is densely populated, requiring careful navigation for new entrants.
- Expiration of the patent opens opportunities for generic entry, but ongoing innovation in formulations and methods can provide additional protection.
- Strategic R&D should consider alternative chemical scaffolds and novel delivery mechanisms within the existing patent terrain.
- Due diligence is crucial when developing new compounds or formulations to avoid patent infringement, especially considering overlapping claims in serotonergic agents.
FAQs
1. What is the main chemical class covered by United States Patent 5,164,190?
It primarily protects benzazepine derivatives, a class of heterocyclic compounds associated with serotonergic modulation.
2. Are the claims of the '190 patent still enforceable?
No. Given its issue date in 1992 and expiry around 2006, the patent's enforceable life has lapsed, opening the space for generic development.
3. Can newer drugs still infringe on the '190 patent?
No, as the patent is expired. Modern compounds utilizing similar benzazepine frameworks would only infringe if they replicate the patented claims during the patent term, which has now ended.
4. How does this patent influence current CNS drug development?
While expired, it historically informed the design of serotonergic agents. Its broad claims in benzazepine chemistry have influenced subsequent patent filings and research.
5. What should developers consider regarding patent landscapes around benzazepine derivatives?
They should analyze current patent filings for novel scaffolds, methods of use, and formulations to ensure freedom-to-operate, especially given active patenting in CNS pharmacology.
References
-
U.S. Patent 5,164,190. "Benzazepine derivatives for the treatment of depression and anxiety." Filed: [Date], Issued: 1992.
-
Prior art references and related patents cited within the patent file.
-
Patent landscape reports on serotonergic agents (2010-2020) [e.g., Pharmaceutical Patent Landscapes, SCRIP Intelligence].
-
FDA and patent expiration timelines for CNS therapeutics referencing benzazepine compounds.
